Race, Ethnicity, and Diffuse Parenchymal Lung Disease
The purpose of this study is to identify factors that contribute to higher mortality rates among blacks and Hispanics with diffuse parenchymal lung disease.
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Diffuse Parenchymal Lung Disease
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Determinants of Outcome in Diffuse Parenchymal Lung Disease|
Plasma/serum, DNA, and circulating cells and endothelial microparticles will be collected and processed.
|Study Start Date:||July 2006|
|Study Completion Date:||August 2013|
|Primary Completion Date:||August 2013 (Final data collection date for primary outcome measure)|
It is well known that both socioeconomic and biological factors may contribute to race- and ethnicity-based health disparities. Black and Hispanic Americans have worse access to healthcare services and tend to receive care from physicians who cannot themselves access the same services for their patients that physicians who care for white patients can. These factors may play important roles in the development and maintenance of health disparities. In addition, biological differences may contribute to disparities. We propose to identify factors that explain survival disparities in a group of lung diseases called diffuse parenchymal lung diseases (DPLDs), including a severe form of DPLD called idiopathic pulmonary fibrosis (IPF). We will follow patients with DPLD at our center and measure both social and biological factors to try to identify the factors that lead to survival disparities between races. Results of this study will be used to design clinical trials aimed at reducing these disparities.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00453713
|United States, New York|
|Columbia University Medical Center|
|New York, New York, United States, 10032|
|Principal Investigator:||David J Lederer, M.D.||Columbia University|